Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RELATIVITY-106: Nivolumab + Relatlimab + Bevacizumab in First-line Advanced/Metastatic Hepatocellular Carcinoma
2024-510649-33-00Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 14
01
Overview
Phase 2, randomised trial in hepatocellular carcinoma (HCC) comparing Nivolumab + Relatlimab + Bevacizumab with Nivolumab + Relatlimab + Placebo (Sodium Chloride) (2 arms). Primary endpoints: Dose-limiting toxicity rate (Part 1) and Objective response rate (Part 2). Started Apr 2024; status: completed.
02
Drugs
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2024-510649-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510649-33-00.